Discover
ZNTL
Zentalis Pharmaceuticals, Inc.
4.36
2 x 3.40
2 x 5.52
bid
ask
-
0.49
10.21%
2 @ 04:00 PM
4.30 -0.06 (1.26%)
| Ytd | 222.59% | |
| 1y | 265.97% |
4.28
day range
4.95
1.15
52 week range
6.95
| Open | 4.80 | Prev Close | 4.85 | Low | 4.28 | High | 4.95 | Mkt Cap | 310.02M |
| Vol | 1.08M | Avg Vol | 2.25M | EPS | -1.74 | P/E | N/A | Forward P/E | -0.89 |
| Beta | 1.74 | Short Ratio | 3.17 | Inst. Own | 98.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.95 | 200-d Avg | 2.60 | 1yr Est | 9.50 |
| Income Statement | |||
| Operating Expenses | 37.85M | ||
| Research and Development Expense | 28.72M | ||
| Selling, General and Administrative Expense | 9.14M | ||
| Operating Income | -37.85M | ||
| Income Tax Expense | 120.00K | ||
| Net Income | -35.35M | ||
| Net Income Common Stock | -35.35M | ||
| Net Income Common Stock (USD) | -35.35M | ||
| Consolidated Income | -35.35M | ||
| Earnings per Basic Share | -0.50 | ||
| Earnings per Basic Share (USD) | -0.50 | ||
| Earnings per Diluted Share | -0.50 | ||
| Earning Before Interest & Taxes (EBIT) | -35.23M | ||
| Earning Before Interest & Taxes (USD) | -35.23M | ||
| Weighted Average Shares | 70.26M | ||
| Weighted Average Shares Diluted | 70.26M | ||
| Balance Sheet | |||
| Cash and Equivalents | 34.56M | ||
| Cash and Equivalents (USD) | 34.56M | ||
| Investments | 179.83M | ||
| Investments Current | 179.83M | ||
| Current Assets | 218.10M | ||
| Property, Plant & Equipment Net | 28.25M | ||
| Total Assets | 253.07M | ||
| Total Debt | 34.65M | ||
| Current Liabilities | 35.24M | ||
| Debt Non-Current | 34.65M | ||
| Total Liabilities | 70.39M | ||
| Accumulated Retained Earnings (Deficit) | -1.23B | ||
| Accumulated Other Comprehensive Income | -50.00K | ||
| Shareholders Equity | 182.68M | ||
| Shareholders Equity (USD) | 182.68M | ||
| Assets Non-Current | 34.97M | ||
| Total Debt (USD) | 34.65M | ||
| Liabilities Non-Current | 35.15M | ||
| Trade and Non-Trade Payables | 7.38M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 151.00K | ||
| Net Cash Flow from Financing | -1.12M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -4.07M | ||
| Capital Expenditure | -34.00K | ||
| Issuance (Purchase) of Equity Shares | -1.12M | ||
| Net Cash Flow from Investing | 30.01M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 30.05M | ||
| Net Cash Flow from Operations | -32.96M | ||
| Share Based Compensation | 3.20M | ||